T0	Participants 58 83	intrahepatic cholestasis.
T1	Participants 278 289	multicenter
T2	Participants 402 450	cholestatic patients with chronic liver disease.
T3	Participants 464 703	220 inpatients (26% chronic active hepatitis, 68% cirrhosis, 6% primary biliary cirrhosis) with stable (1 month or more) at least twofold increases in serum total and conjugated bilirubin and alkaline phosphatase volunteered for the trial.